Business
Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025
NEWARK, CALIFORNIA / ACCESS Newswire / January 29, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company")will host an in-person and virtual
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":"NEWARK, CALIFORNIA / ACCESS Newswire / January 29, 2025 / Protagonist Therapeutics, Inc. (\"Protagonist\" or the \"Company\")will host an in-person and virtual investor event on Thursday, February 6, 2025, at 10:30 AM ET in New York. To register, click here.The event will feature key opinion leader (KOL) insights from Andrew Kuykendall, MD (Moffitt Cancer Center) and Joseph Michael Scandura, MD, PhD (Weill Cornell Medicine), who will discuss the unmet medical need and current treatment landscape for patients with the rare chronic blood disorder polycythemia vera (PV) in the context of the opportunity for Rusfertide.In addition, the event will review the Phase 2 PACIFIC data, the Phase 2 REVIVE data, and the Rusfertide Phase 3 VERIFY study design. The VERIFY topline results are expected in March 2025. In addition, company management will provide a brief snapshot of the commercial opportunity for Rusfertide.A live question and answer session will follow the formal presentations. An informal lunch will be provided from 12:00-1:00 PM ET for in-person attendees, with an opportunity to meet the participants.About Joseph Michael Scandura, MD, PhDJoseph Michael Scandura, MD, PhD received a B.S. in Electrical Engineering from Cornell Ithaca in 1987, and an MS in Biomedical Engineering at the University of Pennsylvania in 1992. He completed the MD/PhD program in Biochemistry at Temple University in 1997. His doctoral work investigating critical interactions between platelets and coagulation factors led to three first-authored papers in Biochemistry. Following his residency in internal medicine-research track at Weill Medical College, New York Presbyterian Hospital from 1997-1999, Dr. Scandura did a Fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center from 1999-2003. Dr. Scandura was appointed Instructor on the Leukemia Service at Memorial in 2003, and an Instructor in Clinical Medicine at Weill Medical College in 2004. He served as an inpatient attending on the Memorial Leukemia Service and outpatient Leukemia Clinic. In 2006, Dr. Scandura joined the Division of Hematology and Medical Oncology at Weill/Cornell to serve in the Leukemia Program. He is Associate Professor of Medicine at Weill Cornell Medical College, and Associate Attending Physician at the New York-Presbyterian Hospital. Dr. Scandura contributes as atten...